Bortezomib
Proteasome inhibitor for multiple myeloma.
What it is
Bortezomib (Velcade) is a proteasome inhibitor FDA-approved for multiple myeloma and mantle cell lymphoma. While not strictly a peptide, it contains a peptide-boronate structure that places it in some peptide-related categorizations.
Mechanism of action
Reversible inhibition of the 26S proteasome, the cellular protein degradation machinery. Inhibition leads to accumulation of misfolded and damaged proteins, triggering apoptosis preferentially in cancer cells with high protein turnover (particularly multiple myeloma cells).
Approved indications
- Multiple myeloma
- Mantle cell lymphoma
Why this is out of scope at The Tide
Specialty hematology/oncology medication. Multiple myeloma and lymphoma require coordinated oncology care including chemotherapy regimens and supportive care that fall entirely outside our practice scope.
Where to learn more
Medical oncology, particularly hematologic oncology.